TESLASCAN
LOE Approachingmangafodipir trisodium
NDAINJECTIONINJECTABLE
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESLASCAN (mangafodipir trisodium) is a parenteral contrast agent approved in 1997 for diagnostic imaging applications. It is administered via injection and functions as a magnetic resonance imaging (MRI) contrast medium. The drug is used to enhance visualization of specific tissue structures during MRI procedures.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a contracting team focused on defending market share rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TESLASCAN offers minimal linked job opportunities, reflecting its mature, late-lifecycle status with zero current openings tracked. Roles on this product focus primarily on maintaining market presence and managing the transition toward genericization rather than growth or innovation.
Field SalesBrand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.